有潜力的国产新药,开始获得更多的市场谈判空间。9月27日,科弈药业宣布,与美国生物医药企业VRise Therapeutics 达成战略合作,双方就全球首个并联增强型双靶向CAR-T细胞治疗产品KQ-2003(靶向BCMA/CD19)签署独家印度区域授权许可协议。不仅如此,两个月前(7月22日),科弈药业还与美国生物药企ERIGEN就KQ-2003达成战略合作,后者将获得KQ-2003在大中华区...
Source Link有潜力的国产新药,开始获得更多的市场谈判空间。9月27日,科弈药业宣布,与美国生物医药企业VRise Therapeutics 达成战略合作,双方就全球首个并联增强型双靶向CAR-T细胞治疗产品KQ-2003(靶向BCMA/CD19)签署独家印度区域授权许可协议。不仅如此,两个月前(7月22日),科弈药业还与美国生物药企ERIGEN就KQ-2003达成战略合作,后者将获得KQ-2003在大中华区...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.